Tag: flu

  • Newly identified antibodies target a hard-to-spot region of the influenza virus

    Newly identified antibodies target a hard-to-spot region of the influenza virus

    [ad_1]

    Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was published today in Immunity.

    Influenza, or flu, sickens millions of people across the globe each year and can lead to severe illness and death. While vaccination against influenza reduces the burden of the disease, updated vaccines are needed each season to provide protection against the many strains and subtypes of the rapidly evolving virus. Vaccines that provide protection against a broad range of influenza viruses could prevent outbreaks of new and reemerging flu viruses without the need for yearly vaccine reformulation or vaccinations. 

    One way to improve influenza vaccines and other countermeasures is to identify new targets on the virus’s surface proteins in “conserved” regions-;portions that tend to be relatively unchanged between different strains of the virus. Influenza NA is a surface protein containing a globular head portion and a narrow stalk portion. The underside of the NA head contains a highly conserved region with targets for antibodies-;known as epitopes-;that make it vulnerable to antibody binding and inhibition of the virus, as well as not being impacted by mutations common in drug-resistant strains. This region is termed the “dark side” due to its partially hidden location and relatively unexplored characteristics.

    The researchers isolated human antibodies that target the NA dark side from the blood of two people who had recovered from influenza type A subtype H3N2, a major subtype of seasonal flu viruses. In lab tests, the antibodies inhibited propagation of viruses from subtype H2N2, the subtype that caused pandemic influenza in 1957-58, and H3N2 viruses from humans, swine, and birds. The antibodies also protected mice from lethal infection by a subtype H3N2 virus when given to the animals either one day before or two days after infection, showing that the antibody may treat and prevent influenza in this model. 

    The scientists analyzed the structure of two of the antibodies while bound to NA using advanced microscopy techniques known as cryogenic electron microscopy. Each antibody targeted different, nonoverlapping regions of the dark side, demonstrating that this region has multiple areas that may be useful to explore for countermeasure development. 

    These findings show that the NA dark side has unique, previously untapped epitopes that could be applied to the development of new vaccine and therapeutic strategies. They suggest that antibodies targeting the NA dark side could be useful in combination with antivirals or other types of antibodies for interventions against influenza, as they are effective against influenza viruses with drug-resistant mutations. The researchers also note that NA dark side targets could be included in the next generation of broadly protective vaccines against influenza.

    Source:

    Journal reference:

    Lederhofer, J., et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity. doi.org/10.1016/j.immuni.2024.02.003.

    [ad_2]

    Source link

  • Study reveals BCG vaccine’s unexpected role in fighting influenza

    Study reveals BCG vaccine’s unexpected role in fighting influenza

    [ad_1]

    As Canada’s flu season collides with record strep A cases and ongoing COVID-19 concerns, a new study is shedding light on our understanding of respiratory immune responses. Scholars from the Research Institute of the McGill University Health Centre (RI-MUHC) have discovered a surprising facet about a century-old vaccine for tuberculosis, Bacillus Calmette Guérin (BCG). The study, published in the journal Nature Immunology, uncovered a previously unknown mechanism that extends the vaccine’s shield to combat influenza A virus-;the most prevalent flu strain.

    The immune interactions involved here can ‘train’ the lungs, which are frequently exposed to infectious agents in the environment. If we can map out the protective immune pathways involved in the lungs, this will revolutionize our conceptual and clinical approaches in developing vaccines against infections, including emergent respiratory viruses.”


    Maziar Divangahi, lead author, pulmonary immunologist, senior scientist at the RI-MUHC, and Professor of Medicine at McGill University

    The discovery paves the way for future studies to assess whether BCG could be used to prevent other emergent viruses. Notably, research on the vaccine’s protection against COVID-19 has had promising results.

    Source:

    Journal reference:

    Tran, K. A., et al. (2024). BCG immunization induces CX3CR1hi effector memory T cells to provide cross-protection via IFN-γ-mediated trained immunity. Nature Immunology. doi.org/10.1038/s41590-023-01739-z.

    [ad_2]

    Source link

  • Researchers develop promising recombinant flu vaccine using nanoliposome technology

    Researchers develop promising recombinant flu vaccine using nanoliposome technology

    [ad_1]

    Recombinant protein vaccines, like the Novavax vaccine used to fight COVID-19, offer several advantages over conventional vaccines.

    They’re easy to precisely produce. They’re safe, and potentially more effective. And they could require smaller doses.

    Because of these traits, there is much interest in developing recombinant influenza vaccines. To date, however, the Food and Drug Administration has approved only one such vaccine.

    A University at Bufalo-led research team hopes to add to that number. It is developing a new recombinant flu vaccine – described in a study published today in the journal Cell Reports Medicine – that has the potential to compete with existing vaccines.

    Because of the variable nature of the viruses that cause influenza, current vaccines are not optimally effective among the overall population. We believe our vaccine candidate has the potential to improve upon this by inducing stronger and broader immunity, and reducing the likelihood of illness and death.”


    Jonathan Lovell, PhD, study senior co-author, SUNY Empire Innovation Professor in the Department of Biomedical Engineering at UB

    Conventional flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease. They are made using fertilized chicken eggs or, less commonly, through cell culture-based production.

    The vaccine the UB-led team is developing is based on a nanoliposome – a tiny spherical sac – that Lovell and colleagues created called cobalt-porphyrin-phospholipid, or CoPoP. The CoPoP platform enables immune response promoting proteins to be displayed on the surface of the nanoliposome, resulting in potent vaccine efficacy.

    (While not part of this study, the CoPoP vaccine platform underwent phase 2 and phase 3 clinical trials in South Korea and the Philippines as a COVID-19 vaccine candidate. This is a partnership between UB spinoff company POP Biotechnologies, co-founded by Lovell, and South Korean biotech company EuBiologics.)

    Alone, these nanoliposomes do not fight disease. But when combined with recombinant influenza proteins that can be generated based on genetic information from viruses, they enhance the immune system’s response to disease.

    In the new study, the team attached to the nanoliposome a total of six proteins – three each from two different protein groups, hemagglutinins and neuraminidases. The team also added two adjuvants (PHAD and QS21) to boost immune response.

    Researchers evaluated the resulting “hexaplex” nanoliposome in animal models with three common flu strains: H1N1, H3N2 and type B.

    Even when administered in low doses, the hexaplex nanoliposome provided superior protection and survival from H1 and N1 when compared to Flublok, which is the sole licensed recombinant influenza vaccine in the U.S., and Fluaid, an egg-based vaccine. Tests showed comparable levels of protection against H3N2 and type B viruses.

    The tests were performed via vaccination and through blood serum transfer from vaccinated mice into non-vaccinated mice.

    “The combination of the two groups of proteins led to synergistic effects. In particular, the adjuvanted nanoliposomes excelled in the production of functional antibodies and the activation of T cells, which are critical to fighting off serious infection of the flu,” says lead author Zachary Sia, a PhD candidate in Lovell’s lab.

    Bruce Davidson, PhD, research associate professor of anesthesiology in the Jacobs School of Medicine and Biomedical Sciences at UB, is a senior co-author of the study.

    He says “using not only hemagglutinin but also neuraminidase antigens to create vaccines is important because it translates into broader immunity and companies will be able to create more doses with less materials. That’s critical for not only the flu but also potential outbreaks like what we saw with COVID-19. There is still much work to be done in fully testing and validating this flu technology, but at this point these early results are quite promising.”

    In addition to UB, study co-authors include scientists from McGill University.

    Patents related to this work have been filed with The Research Foundation for the State University of New York. Lovell and study co-author Wei-Chiao Huang, postdoctoral scholar in Lovell’s lab, are employed by POP Biotechnologies.

    The study was funded, in part, by the National Institutes of Health.

    Source:

    Journal reference:

    Sia, Z. R., et al. (2024) Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine. Cell Reports Medicine. doi.org/10.1016/j.xcrm.2024.101433.

    [ad_2]

    Source link

  • October births linked to higher flu vaccination and lower diagnosis rates

    October births linked to higher flu vaccination and lower diagnosis rates

    [ad_1]

    Children born in October are both more likely to be vaccinated against influenza and least likely to be diagnosed with influenza compared with children born in other months, finds a US study published by The BMJ today.

    The results suggest that birth month is associated with both timing of flu vaccination and the likelihood of a flu diagnosis – and that October is the optimal time for young children to have a flu shot, in line with current recommendations.

    Annual influenza vaccination is particularly important for young children, who are at higher risk of flu and severe infection requiring admission to hospital. Vaccination is recommended during September or October to maximize immunity during the peak flu season. 

    Among young children in the United States, preventive care visits tend to occur during birth months and are a convenient time to receive the influenza vaccine, but large scale studies of the optimal timing of vaccination are unavailable.

    To address this, researchers set out to assess the optimal timing of influenza vaccination in young children.

    Using health insurance claims data, they identified over 800,000 children aged 2-5 years who received an influenza vaccination between 1 August and 31 January during 2011-18. They then analyzed rates of diagnosed influenza among these children by birth month.

    After accounting for a range of potentially influential factors such as age, sex, existing conditions, healthcare use and family size, the results show that October was the most common month for children to be vaccinated.

    Children born in October also had the lowest rate of influenza diagnosis. For example, among children born in August, the average rate of influenza diagnosis across flu seasons studied was 3% compared with 2.7% for children born in October and 2.9% for those born in December.

    This is an observational study and the authors acknowledge that their findings are limited to insured children who received medical care. Nor can they rule out the possibility that other unmeasured factors may have influenced their results.

    Nevertheless, results were similar after additional analyses to evaluate whether the relation between birth month and influenza risk was due to chance, providing greater confidence in their conclusions.

    “Our findings suggest that US public health interventions focused on vaccination of young children in October may yield the best protection in typical flu seasons,” they say. 

    “The study’s findings are consistent with current recommendations promoting October vaccination,” they add.

    Source:

    Journal reference:

    Worsham, C. M., et al. (2024). Optimal timing of influenza vaccination in young children: population based cohort study. BMJ. doi.org/10.1136/bmj-2023-077076.

    [ad_2]

    Source link

  • CDC studies show effectiveness of flu vaccines across all age groups

    CDC studies show effectiveness of flu vaccines across all age groups

    [ad_1]

    The prospect of the worrisome triple threat of COVID, RSV and flu was assuaged last year by the effectiveness of flu vaccines. Two recent studies from the Centers for Disease Control and Prevention’s VISION Network have found that flu vaccines were effective for all ages against both moderate and severe flu in the U.S. during the 2022-2023 flu season.

    Both the pediatric and adult VISION Network studies analyzed flu-associated emergency department (E.D.)/urgent care visits (indicative of moderate disease) and hospitalization (indicative of severe disease) from October 2022 through March 2023, a flu season in which far fewer individuals were social distancing or wearing masks than during the two previous flu seasons.

    Vaccination reduced the risk of flu-related E.D./urgent care visits and hospitalization for those 6 months to 17 years by almost half. For adults, regardless of age, vaccination reduced the risk of E.D. urgent care visits by almost half and reduced the risk of hospitalization by slightly more than a third.

    These results led the authors of both studies to conclude that flu vaccination is likely to substantially reduce illness, death and strain on healthcare resources.

    We study the effectiveness of flu and other vaccines to ensure that our processes for forecasting the most effective vaccines are working well and therefore might potentially also be translatable to other diseases as well. Given influenza’s significant disease burden — for example the H1N1 (swine) flu killed over a quarter of a million people worldwide in 2009-2010 — we want to make sure that we understand virus trends as well as other factors and that we’re continuing to do as well as and as much as we can to reduce the flu disease burden.”


    Shaun Grannis, M.D., M.S., co-author of both the pediatric and adult VISION Network studies, Regenstrief Institute vice president for data and analytics and family practice physician

    Both the pediatric and adult studies evaluated electronic health record (EHR) data from sites across three healthcare systems in California, Utah, Minnesota and Wisconsin.

    Flu vaccine effectiveness: 2022-2023 flu season for ages 6 months to 17 years

    Vaccination reduced the risk of flu-related E.D./urgent care visits (moderate disease) by 48 percent and hospitalization (severe disease) by 40 percent overall across ages 6 months to 17 years. Broken down by age, risk reduction was greater for those age 6 months to 4 years than older children and adolescents.

    Ages 6 months to four years

    • Vaccination reduced the risk of E.D./urgent care visits (moderate disease) by 53 percent.
    • Vaccination reduced the risk of hospitalization (severe disease) by 56 percent.

    Ages 5 to 17 years

    • Vaccination reduced the risk of E.D./ urgent care visits (moderate disease) by 38 percent.
    • Vaccination reduced the risk of hospitalization by 46 percent.

    Approximately 30 percent of E.D./critical care visits for acute respiratory illness in children and adolescents were positive for flu, as were 14 percent of hospitalizations.

    “Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season, VISION Network” is published in Clinical Infectious Diseases.

    Flu vaccine effectiveness: 2022-2023 flu season for ages 18-64

    Vaccine effectiveness was 45 percent against E.D./critical care visits(moderate disease) for adults under age 65. Effectiveness against hospitalization (severe disease) was 23 percent.

    Adults younger than 65 typically received standard-dose inactivated vaccines.

    Flu vaccine effectiveness: 2022-2023 flu season for ages 65 and older

    Vaccine effectiveness was 41 percent against both flu-associated E.D./urgent care visits (moderate disease) and hospitalization (serious disease) for this age group.

    Adults age 65 and older typically received enhanced vaccine products.

    “Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023” is published in the Journal of Infectious Diseases.

    “As with COVID, the dynamics of flu differs between children and adults. But we found that for both children and adults, vaccination significantly reduced the need for trips to the E.D, or critical care center and for hospitalization for flu-related illnesses last flu season and this is encouraging,” said Dr. Grannis. “I’m hopeful that we will see similar or even better vaccine effectiveness during the current flu season. Even if they do experience symptoms, people who are vaccinated typically tend to have milder, shorter cases of the flu, a viral illness which can carry a severe disease burden.

    “The vaccine effectiveness we saw in last year’s flu season is encouraging. As both a research scientist and a primary care physician, I urge everyone to be vaccinated for flu this year and every year – it’s good for each person’s health and the health of your community.”

    Source:

    Journal reference:

    Tenforde, M. W., et al. (2024) Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023. The Journal of Infectious Diseases. doi.org/10.1093/infdis/jiad542.

    [ad_2]

    Source link

  • Fluid-filled lung sac found to be the hub for virus-eating cells

    Fluid-filled lung sac found to be the hub for virus-eating cells

    [ad_1]

    Scientists have long thought of the fluid-filled sac around our lungs merely as a cushion from external damage. Turns out, it also houses potent virus-eating cells that rush into the lungs during flu infections.

    Not to be confused with phages, which are viruses that infect bacteria, these cells are macrophages, immune cells produced in the body. 

    “The name macrophage means ‘big eater.’ They gobble up bacteria, viruses, cancer cells, and dying cells. Really, anything that looks foreign, they take it up and destroy it,” said UC Riverside virologist Juliet Morrison, who led the discovery team. “We were surprised to find them in the lungs because nobody has seen this before, that these cells go into the lung when there’s an infection.”

    A paper published in the Proceedings of the National Academy of Sciences details how during an influenza infection, macrophages leave the exterior cavity and cross into the lungs where they decrease inflammation and reduce levels of disease. 

    This study shows it’s not just what happens in the lung that matters, but also what’s outside of the lung. Cell types not normally connected to the lung can have outsized impacts on lung disease and health.”


    Juliet Morrison, UC Riverside virologist

    There are three main cavities in the body: one around the heart, the abdominal cavity, and the pleural cavity surrounding the lungs. “Because it contains fluid, it prevents the lungs from collapsing. However, people have not thought much about the pleural cavity being a whole organ within itself. This research may change that perception,” Morrison said.

    Initially, the researchers set out to understand the more general question of what types of cells are present in the lungs during flu infections. They took existing data on lung-related genes from studies of mice that either died from the flu or survived. They then mined the data using an algorithm to predict cell types that change in the lungs during infections. 

    “We took big data and broke it down to assign which potential immune cells are in the lung tissues. That’s where I got a hint that maybe we had a previously unknown external source of cells in the lung,” Morrison said. 

    Next, using a laser-based technique, the team tracked macrophages going into the lungs of mice, and observed what happened if they took these cells out of the equation. “When you take them out of the mouse you see more disease and more lung inflammation,” Morrison said. 

    Morrison says she hopes this study will encourage other scientists to reevaluate data sets from older studies. “Our approach was to take information already out there and put it to new use, and we were able to see something new,” she said. 

    Moving forward, the research team is hoping to determine which proteins “tell” the macrophages to move into the lungs. Once the protein signals have been identified, it may be possible to create drugs that boost either the number of macrophages, or their activity.

    The strategy of boosting human defenses to infection, rather than developing another antiviral, could offer people a flu treatment that would be more effective for much longer. Morrison became interested in host therapeutics because antibiotic and antiviral resistance to drugs is a growing problem.

    This problem occurs when germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them. Misuse and overuse of the drugs is accelerating the problem. According to the Centers for Disease Control and Prevention, more than 2.8 million drug-resistant infections occur each year in the U.S., and more than 35,000 people die as a result. 

    “If we can boost what resolves infection in us, we probably have a better shot. We’re less likely to have resistance. The immune system is so complicated, but it’s our best bet in the long run to work with what we have rather than chase viruses that continue to escape our therapeutics,” Morrison said. 

    Source:

    Journal reference:

    Stumpff, J. P., et al. (2023). Pleural macrophages translocate to the lung during infection to promote improved influenza outcomes. PNAS. doi.org/10.1073/pnas.2300474120.

    [ad_2]

    Source link

  • New study finds 4’-fluorouridine effective against avian influenza in vitro and in vivo

    New study finds 4’-fluorouridine effective against avian influenza in vitro and in vivo

    [ad_1]

    In a recent study published in the journal PLOS Pathogens, researchers from the United States of America (US) investigated the resistance profile of 4’-fluorouridine (4’-FlU) against an avian influenza pandemic A/CA/07/2009 (H1N1, short for hemagglutinin 1 neuraminidase 1) (CA09).

    Bird flu virus 3d rendering medical illustration surface structure avian influenza
    Study: Influenza A virus resistance to 4’-fluorouridine coincides with viral attenuation in vitro and in vivo. Image Credit: joshimerbin/Shutterstock.com

    They found that the molecule could overcome resistance in six identified escape lineages of the virus in vitro and showed promising results in mice and ferret models.

    Background

    Seasonal influenza viruses significantly impact public health and the economy. Every year, around one billion people worldwide get infected with the virus, and millions require hospitalization and advanced medical care. In interpandemic years, more than 600,000 people die from the disease. When zoonotic influenza viruses spill over into the human population, they can cause large-scale pandemics with even higher case fatalities. Existing influenza vaccines offer moderate protection, but efficacy diminishes in vulnerable populations and during poorly matched or pandemic virus strains.

    Food and Drugs Administration (FDA)-approved antivirals, including adamantes, neuraminidase inhibitors, and baloxavir marboxil, face challenges with low genetic barriers to viral resistance.

    Several antiviral resistance challenges persist, including adamantes’ widespread M2 S31N mutation, neuraminidase inhibitors’ rapid emergence of resistance, baloxavir marboxil’s swift treatment-emergent resistance, and uncertainties surrounding favipiravir’s clinical impact, despite a high resistance barrier.

    In previous studies, 4’-FlU, a broad-spectrum nucleoside analog, was found to be effective against various ribonucleic acid (RNA) viruses, including beta-coronaviruses, respiratory syncytial virus (RSV), and avian influenza viruses, and displayed broad-spectrum activity and a wide therapeutic time window.

    In the present study, researchers explored the therapeutic potential of 4’-FlU via resistance profiling and assessment of the pathogenesis and fitness of resistant recombinants in vitro and in vivo.

    About the study

    The study involved the gradual adaptation of recombinant virus CA09 (recCA09) to 4’-FlU through dose-escalation serial passaging in vitro in six independent lineages. Progeny virus titers were determined at each passage, and whole genome sequencing was conducted on 4’-FlU-experienced virus populations and dimethyl sulfoxide (DMSO)-treated control populations to identify allele-dominant mutations in RNA-dependent RNA polymerase (RdRp).

    The mutations were localized using structural models. The process aimed to assess the development of resistance and understand the genetic changes associated with tolerance to 4’-FlU. Dose-response assays were conducted against recCA09 to determine inhibitory concentrations (EC50 and EC90) of 4’-FIU.

    To assess the resistance profile of 4′-FlU against influenza viruses, in vitro and in vivo models, including cells, mice, and ferrets, were employed. In addition, in silico modeling was used for mechanistic characterization. The virus was intranasally inoculated.

    The viral load was periodically monitored in nasal lavages (of ferrets) and respiratory tissues of mice and ferrets, extracted 4 or 8 days after infection. Statistical analysis involved the use of Student’s t-test and analysis of variance (ANOVA) to compare parameters between the groups.

    Results and discussion

    The EC50 and EC90 of 4’-FIU were found to be 0.14 and 0.24 μM respectively. During the in vitro adaptation of the virus to 4’-FlU six independent escape lineages with distinct mutations in the recCA09 background were generated. A 2–25-fold increase was observed in EC99 concentrations of 4’-FlU against the different lineages, confirming moderate resistance.

    No combinations of mutations conferring moderate resistance to 4’-FlU were found in available complete influenza A virus (IAV) genome sequences. The mutations’ low individual frequency validated 4’-FIU’s efficacy against circulating human and avian IAVs.

    The researchers could identify specific residues crucial for shaping the central cavity of the RdRP as key determinants in moderately reducing polymerase susceptibility to 4’-FlU inhibition. Additionally, they suggest that a substantial genetic barrier may hinder the emergence of more robust resistance.

    Escape was found to arise from individual, additive or synergistic mutations. All the variants showed impaired fitness and attenuation in cell culture and mice models. Although the resistant variants remained pathogenic in the mice, their moderate resistance to 4’-FlU could be overcome pharmacologically in vivo.

    Oral administration of 4’-FlU at either the lowest (2 mg/kg) or elevated (10 mg/kg) dose was found to effectively overcome resistance, as indicated by the survival of the mice. The positive effect of 4’-FIU was also evidenced by reduced clinical signs and lower tissue virus burden.

    Even for variants with the most robust resistance or residual pathogenicity, their transmission is compromised and/or easily controlled by the standard dose of 4’-FlU. In the ferret model, the 4’-FlU-treated variants (representing four adaptation lineages) showed impaired invasion of the lower respiratory tract, rendering them either transmission-incompetent or blocking their spread to untreated sentinels.

    The study’s limitations include uncertainty about whether the observed 4’-FlU resistance profile, determined in various experimental systems, equally applies to the human host.

    Conclusion

    In conclusion, the present study elucidates mechanisms diminishing the susceptibility of the IAV polymerase complex to 4’-FIU. In mice and ferret models, it is shown that while escape from 4’-FlU is possible, it is associated with viral attenuation and diminished transmission competence.

    Thus, 4’-FlU-resistant virus populations are found incapable of attaining clinical significance or enduring in circulation in real-world scenarios, highlighting the compound’s sustained therapeutic potential. In the future, studies exploring the potential human application and dose levels of 4’-FIU could be conducted.

    [ad_2]

    Source link

  • Do we simply not care about old people?

    Do we simply not care about old people?

    [ad_1]

    The covid-19 pandemic would be a wake-up call for America, advocates for the elderly predicted: incontrovertible proof that the nation wasn’t doing enough to care for vulnerable older adults.

    The death toll was shocking, as were reports of chaos in nursing homes and seniors suffering from isolation, depression, untreated illness, and neglect. Around 900,000 older adults have died of covid-19 to date, accounting for 3 of every 4 Americans who have perished in the pandemic.

    But decisive actions that advocates had hoped for haven’t materialized. Today, most people — and government officials — appear to accept covid as a part of ordinary life. Many seniors at high risk aren’t getting antiviral therapies for covid, and most older adults in nursing homes aren’t getting updated vaccines. Efforts to strengthen care quality in nursing homes and assisted living centers have stalled amid debate over costs and the availability of staff. And only a small percentage of people are masking or taking other precautions in public despite a new wave of covid, flu, and respiratory syncytial virus infections hospitalizing and killing seniors.

    In the last week of 2023 and the first two weeks of 2024 alone, 4,810 people 65 and older lost their lives to covid — a group that would fill more than 10 large airliners — according to data provided by the CDC. But the alarm that would attend plane crashes is notably absent. (During the same period, the flu killed an additional 1,201 seniors, and RSV killed 126.)

    “It boggles my mind that there isn’t more outrage,” said Alice Bonner, 66, senior adviser for aging at the Institute for Healthcare Improvement. “I’m at the point where I want to say, ‘What the heck? Why aren’t people responding and doing more for older adults?’”

    It’s a good question. Do we simply not care?

    I put this big-picture question, which rarely gets asked amid debates over budgets and policies, to health care professionals, researchers, and policymakers who are older themselves and have spent many years working in the aging field. Here are some of their responses.

    The pandemic made things worse. Prejudice against older adults is nothing new, but “it feels more intense, more hostile” now than previously, said Karl Pillemer, 69, a professor of psychology and gerontology at Cornell University.

    “I think the pandemic helped reinforce images of older people as sick, frail, and isolated — as people who aren’t like the rest of us,” he said. “And human nature being what it is, we tend to like people who are similar to us and be less well disposed to ‘the others.’”

    “A lot of us felt isolated and threatened during the pandemic. It made us sit there and think, ‘What I really care about is protecting myself, my wife, my brother, my kids, and screw everybody else,’” said W. Andrew Achenbaum, 76, the author of nine books on aging and a professor emeritus at Texas Medical Center in Houston.

    In an environment of “us against them,” where everybody wants to blame somebody, Achenbaum continued, “who’s expendable? Older people who aren’t seen as productive, who consume resources believed to be in short supply. It’s really hard to give old people their due when you’re terrified about your own existence.”

    Although covid continues to circulate, disproportionately affecting older adults, “people now think the crisis is over, and we have a deep desire to return to normal,” said Edwin Walker, 67, who leads the Administration on Aging at the Department of Health and Human Services. He spoke as an individual, not a government representative.

    The upshot is “we didn’t learn the lessons we should have,” and the ageism that surfaced during the pandemic hasn’t abated, he observed.

    Ageism is pervasive. “Everyone loves their own parents. But as a society, we don’t value older adults or the people who care for them,” said Robert Kramer, 74, co-founder and strategic adviser at the National Investment Center for Seniors Housing & Care.

    Kramer thinks boomers are reaping what they have sown. “We have chased youth and glorified youth. When you spend billions of dollars trying to stay young, look young, act young, you build in an automatic fear and prejudice of the opposite.”

    Combine the fear of diminishment, decline, and death that can accompany growing older with the trauma and fear that arose during the pandemic, and “I think covid has pushed us back in whatever progress we were making in addressing the needs of our rapidly aging society. It has further stigmatized aging,” said John Rowe, 79, professor of health policy and aging at Columbia University’s Mailman School of Public Health.

    “The message to older adults is: ‘Your time has passed, give up your seat at the table, stop consuming resources, fall in line,’” said Anne Montgomery, 65, a health policy expert at the National Committee to Preserve Social Security and Medicare. She believes, however, that baby boomers can “rewrite and flip that script if we want to and if we work to change systems that embody the values of a deeply ageist society.”

    Integration, not separation, is needed. The best way to overcome stigma is “to get to know the people you are stigmatizing,” said G. Allen Power, 70, a geriatrician and the chair in aging and dementia innovation at the Schlegel-University of Waterloo Research Institute for Aging in Canada. “But we separate ourselves from older people so we don’t have to think about our own aging and our own mortality.”

    The solution: “We have to find ways to better integrate older adults in the community as opposed to moving them to campuses where they are apart from the rest of us,” Power said. “We need to stop seeing older people only through the lens of what services they might need and think instead of all they have to offer society.”

    That point is a core precept of the National Academy of Medicine’s 2022 report Global Roadmap for Healthy Longevity. Older people are a “natural resource” who “make substantial contributions to their families and communities,” the report’s authors write in introducing their findings.

    Those contributions include financial support to families, caregiving assistance, volunteering, and ongoing participation in the workforce, among other things.

    “When older people thrive, all people thrive,” the report concludes.

    Future generations will get their turn. That’s a message Kramer conveys in classes he teaches at the University of Southern California, Cornell, and other institutions. “You have far more at stake in changing the way we approach aging than I do,” he tells his students. “You are far more likely, statistically, to live past 100 than I am. If you don’t change society’s attitudes about aging, you will be condemned to lead the last third of your life in social, economic, and cultural irrelevance.”

    As for himself and the baby boom generation, Kramer thinks it’s “too late” to effect the meaningful changes he hopes the future will bring.

    “I suspect things for people in my generation could get a lot worse in the years ahead,” Pillemer said. “People are greatly underestimating what the cost of caring for the older population is going to be over the next 10 to 20 years, and I think that’s going to cause increased conflict.”

    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link